BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34746691)

  • 61. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
    Kozlitina J; Smagris E; Stender S; Nordestgaard BG; Zhou HH; Tybjærg-Hansen A; Vogt TF; Hobbs HH; Cohen JC
    Nat Genet; 2014 Apr; 46(4):352-6. PubMed ID: 24531328
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
    Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
    J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
    [TBL] [Abstract][Full Text] [Related]  

  • 63.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children.
    Mancina RM; Sentinelli F; Incani M; Bertoccini L; Russo C; Romeo S; Baroni MG
    Dig Liver Dis; 2016 Jan; 48(1):100-1. PubMed ID: 26520056
    [No Abstract]   [Full Text] [Related]  

  • 65. The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta-analysis of 24,147 subjects.
    Chen X; Zhou P; De L; Li B; Su S
    Mol Genet Genomic Med; 2019 Aug; 7(8):e824. PubMed ID: 31309745
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
    Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
    Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
    Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
    World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
    Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
    Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Coding variants in
    Guzman CB; Duvvuru S; Akkari A; Bhatnagar P; Battioui C; Foster W; Zhang XM; Shankar SS; Deeg MA; Chalasani N; Hardy TA; Kazda CM; Pillai SG
    Hepatol Commun; 2018 May; 2(5):561-570. PubMed ID: 29761171
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association between non-alcoholic fatty liver disease and subclinical hypothyroidism in children with obesity.
    Di Sessa A; Cembalo Sambiase Sanseverino N; De Simone RF; Marrapodi MM; Cirillo G; Umano GR; Guarino S; Papparella A; Miraglia Del Giudice E; Marzuillo P
    J Endocrinol Invest; 2023 Sep; 46(9):1835-1842. PubMed ID: 36828986
    [TBL] [Abstract][Full Text] [Related]  

  • 73. APOC3rs2854116, PNPLA3rs738409, and TM6SF2rs58542926 polymorphisms might influence predisposition of NAFLD: A meta-analysis.
    Tong M; Wang F
    IUBMB Life; 2020 Aug; 72(8):1757-1764. PubMed ID: 32525256
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD.
    Busca C; Arias P; Sánchez-Conde M; Rico M; Montejano R; Martín-Carbonero L; Valencia E; Moreno V; Bernardino JI; Olveira A; Abadía M; González-García J; Montes ML
    Front Pharmacol; 2022; 13():905126. PubMed ID: 36110512
    [No Abstract]   [Full Text] [Related]  

  • 75. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant.
    Mancina RM; Matikainen N; Maglio C; Söderlund S; Lundbom N; Hakkarainen A; Rametta R; Mozzi E; Fargion S; Valenti L; Romeo S; Taskinen MR; Borén J
    J Clin Endocrinol Metab; 2015 May; 100(5):E821-5. PubMed ID: 25763607
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.
    Liu ZT; Chen TC; Lu XX; Cheng J; Xie HY; Zhou L; Zheng SS
    World J Gastroenterol; 2015 Sep; 21(34):10054-6. PubMed ID: 26379412
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 80. TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a "Prudent" Dietary Pattern on Serum Triglyceride Levels.
    Kalafati IP; Dimitriou M; Revenas K; Kokkinos A; Deloukas P; Dedoussis GV
    Nutrients; 2023 Feb; 15(5):. PubMed ID: 36904112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.